AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10839897
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (3.0 microg/kg)
Trial: 10839897
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (1.5 and 3.0 microg/kg)
Trial: 9089424
Drug: Intravenous neu‐metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous neu‐metoclopramide (1.8 mg/kg)
Trial: 9089424
Drug: Intramuscular neu‐metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular neu‐metoclopramide (1.8 mg/kg)
Trial: 9089424
Drug: Intravenous metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoclopramide (1.8 mg/kg)
Trial: 9089424
Drug: Intravenous neu‐metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous neu‐metoclopramide
Trial: 9089424
Drug: Intramuscular neu‐metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular neu‐metoclopramide
Trial: 8262291
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg prostaglandin E2 (PGE2), repeated daily if necessary (group 1)
Trial: 8262291
Drug: 0.50 mg
RxNorm normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 mg prostaglandin E2 (PGE2) (group 2)
Trial: 25518484
Drug: Mouth rinsing
RxNorm normalized name: phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mouth rinsing with 50 ml of 1% urea solution
Trial: 25518484
Drug: Mouth rinsing
RxNorm normalized name: phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mouth rinsing with various concentrations and amounts of urea solution
Trial: 20388471
Drug: Kuntai Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuntai Capsule (6 g three times a day)
Trial: 20388471
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE) (0.3 mg and 0.6 mg alternately once a day, average dose of 0.45 mg/d)
Trial: 11880065
Drug: Single-dose gatifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose gatifloxacin (400 mg)
Trial: 11880065
Drug: 3-day gatifloxacin
RxNorm normalized name: gatifloxacin 3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day gatifloxacin (200 mg daily)
Trial: 11880065
Drug: 3-day ciprofloxacin
RxNorm normalized name: ciprofloxacin 3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day ciprofloxacin (100 mg twice daily)
Trial: 7747859
Drug: Edrophonium 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.75 mg.kg‐1 and atropine 0.015 mg.kg‐1
Trial: 2202550
Drug: Immediate-release indomethacin
RxNorm normalized name: indomethacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release indomethacin capsules, 25 mg given 3-times daily
Trial: 25981871
Drug: Biological explanation
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological explanation
Trial: 23736793
Drug: Autologous platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet-rich plasma (PRP) treatment (9 injections over 1 year, 2.0 to 2.5-fold platelet concentration)
Trial: 14764389
Drug: Perindopril 2
RxNorm normalized name: perindopril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 2 mg/Indapamide 0.625 mg (very low dose combination therapy)
Trial: 14764389
Drug: Perindopril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril plus Indapamide (very low doses)
Trial: 7710569
Drug: Calcium gluconate
RxNorm normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium gluconate (100 mg/kg)
Trial: 2551520
Drug: 3% 2-chloroprocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% 2-chloroprocaine (2-CP) with 3 ml 0.9% NaCl (Control)
Trial: 333341
Drug: Mucolytic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucolytic and decongestive treatment
Trial: 333341
Drug: Previous antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous antibiotic treatment for acute otitis media
Trial: 28827011
Drug: Rotigotine (4-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine (4-16 mg/24 h)
Trial: 23433094
Drug: CHD patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHD patients without acute inflammation and overt iron deficiency (C reactive protein <1 mg/dl and ferritin >30 ng/ml; n=86)
Trial: 17093176
Drug: Iodized peanut
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodized peanut oil (P200, P400, P800 mg I)
Trial: 17093176
Drug: Iodized poppy
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodized poppy seed oil (PS400 mg I)
Trial: 17093176
Drug: Iodized peanut
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodized peanut oil (P400 mg I)
Trial: 15317642
Drug: slow-release bupropion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: slow-release bupropion 150 mg b.i.d.
Trial: 11558493
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil monotherapy
Trial: 11558493
Drug: Calcineurin-inhibitor therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcineurin-inhibitor therapy (ciclosporin or tacrolimus)
Trial: 8013271
Drug: Moguisteine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moguisteine (200 mg t.i.d. for four days)
Trial: 23729104
Drug: Surgery, radiotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery, radiotherapy, and additional chemotherapy
Trial: 18512224
Drug: Weekly regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly regimen (paclitaxel 100 mg/m² weekly for 3 of 4 weeks; carboplatin AUC = 6 mg/mL.min every 4 weeks)
Trial: 18512224
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (paclitaxel 225 mg/m² every 3 weeks; carboplatin AUC = 6 mg/mL.min on Day 1 every 21 days)
Trial: 10989734
Drug: Fosinopril 20
RxNorm normalized name: fosinopril 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril 20 mg/day for 8 weeks, with the possibility to increase treatment to Fosinopril + hydrochlorothiazide after 4 weeks
Trial: 8788082
Drug: Nicotine dermal
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine dermal plaster (21 mg/24 h or 14 mg/24 h)
Trial: 1634054
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg 5-ASA three times daily (n = 64)
Trial: 6229176
Drug: Vancomycin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (15 mg/kg/dose)
Trial: 30126618
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone (96 mg immediately after treatment followed by 48 mg each day for 5 consecutive days)
Trial: 24692737
Drug: Pilocarpine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine (5 mg pilocarpine three times daily, n=5)
Trial: 24692737
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline solution intake, n=6)
Trial: 15788496
Drug: ACVBP (doxorubicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) plus sequential consolidation
Trial: 10826429
Drug: Bowel preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel preparation with oral polyethylene glycol electrolyte solution
Trial: 1641820
Drug: 0.25 mg/kg/24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg/24 h alteplase
Trial: 1641820
Drug: 0.5 mg/kg/24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg/24 h alteplase
Trial: 30644260
Drug: Short-segment fixation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-segment fixation combined with vertebral reconstruction (treatment group)
Trial: 27247511
Drug: Dexmedetomidine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1.0 µg/kg IV loading dose followed by 0.5 µg/kg/hr infusion)
Trial: 20872929
Drug: Memantine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (20 mg per day) for 24 weeks
Trial: 18065586
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron (DI) foodLETs (10 mg)
Trial: 18065586
Drug: Daily multiple-micronutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily multiple-micronutrients (DMM) foodLETs (10 mg Fe)
Trial: 18065586
Drug: Weekly multiple-micronutrient
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly multiple-micronutrient (WMM) foodLETs (20 mg Fe)
Trial: 1371665
Drug: Aprotinin (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (total dose, 6 to 7 x 10(6) KIU)
Trial: 30522524
Drug: DHP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHP treatment
Trial: 27230605
Drug: nab-P/C (nab-paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-P/C (nab-paclitaxel 100 mg/m2 on days 1, 8, and 15 + carboplatin at AUC 6 mg·min/mL on day 1 every 3 weeks)
Trial: 27230605
Drug: sb-P/C (solvent-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sb-P/C (solvent-based paclitaxel 200 mg/m2 on day 1 + carboplatin at AUC 6 mg·min/mL on day 1 every 3 weeks)
Trial: 8699062
Drug: Acyclovir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (800 mg 5 times/day) and prednisolone (0.7 mg/kg for the first 4 days, reduced by 0.1 mg/kg on consecutive days for another 6 days)
Trial: 1896168
Drug: Timolol (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol (topical medication)
Trial: 28168204
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Pioglitazone
Trial: 25526875
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg daily for 7 days, then 850 mg twice a day for the next 5 weeks
Trial: 19298459
Drug: Pioglitazone (15-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15-45 mg day(-1)) added to sulfonylurea
Trial: 19298459
Drug: Pioglitazone (15-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15-45 mg day(-1)) added to metformin
Trial: 19298459
Drug: Gliclazide (80-320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide (80-320 mg day(-1)) + metformin
Trial: 19298459
Drug: Gliclazide (80-320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide (80-320 mg day(-1)) + pioglitazone
Trial: 12145995
Drug: 5'‐DFUR 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'‐DFUR 600 mg/body/day for 6 months and TAM 20 mg/body/day for 2 years (Group A)
Trial: 12145995
Drug: 5'‐DFUR 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'‐DFUR 600 mg/body/day for 2 years and TAM 20 mg/body/day for 2 years (Group B)
Trial: 1968323
Drug: atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol 100 mg od
Trial: 1968323
Drug: propranolol (slow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol (slow release) 160 mg od
Trial: 1968323
Drug: pindolol 5
RxNorm normalized name: pindolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pindolol 5 mg tid
Trial: 1968323
Drug: nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebivolol 5 mg od
Trial: 27342579
Drug: Sucroferric oxyhydroxide
RxNorm normalized name: Sucroferric Oxyhydroxide
DrugBank: Iron sucrose (DB09146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucroferric oxyhydroxide 1.0-3.0 g/day
Trial: 27342579
Drug: Sevelamer carbonate
RxNorm normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer carbonate 2.4-14.4 g/day
Trial: 19267352
Drug: Multi-peptide vaccination
RxNorm normalized name: Multi-peptide vaccination
DrugBank: CoVac-1 (DB16429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-peptide vaccination with 11 HLA‐A*0201‐restricted and two HLA class II synthetic peptides, administered subcutaneously for 18 months or until PSA progression, combined with various adjuvants including imiquimod, GM‐CSF, mucin‐1‐mRNA/protamine complex, and local hyperthermia.
Trial: 19267352
Drug: Imiquimod and
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod and mucin‐1‐mRNA/protamine complex as adjuvants (both are Toll‐like receptor‐7 agonists).
Trial: 11725730
Drug: OC containing
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC containing 0.030 mg of ethinyl estradiol (EE) and 0.15 mg of desogestrel (Group A)
Trial: 11725730
Drug: OC containing
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC containing 0.020 mg of ethinyl estradiol (EE) and 0.15 mg of desogestrel (Group B)
Trial: 9164358
Drug: Theophylline (extended-release)
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline (extended-release)
Trial: 2959198
Drug: Amikacin-ceftazidime-teicoplanin treatment
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin-ceftazidime-teicoplanin treatment
Trial: 15897360
Drug: Amlodipine (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (one of the antihypertensives)
Trial: 15897360
Drug: Ramipril and
RxNorm normalized name: ramipril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril and Metoprolol (other antihypertensives)
Trial: 12324674
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 400 micro g twice daily
Trial: 22583583
Drug: Delayed rebonding
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed rebonding after one month in a simulated oral environment
Trial: 20869557
Drug: 0.3 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 percent solution‐based ciprofloxacin (Ciloxan)
Trial: 15851401
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (daily antioxidant powder containing riboflavin, vitamin E, selenium, and N-acetylcysteine for 20 weeks)
Trial: 12844385
Drug: Fish-oil capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil capsules containing 400 mg DHA/g (200 mg/d) (n=50)
Trial: 12844385
Drug: Placebo containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo containing 810 mg oleic acid/g (400 mg/d) (n=50)
Trial: 8783998
Drug: Direct infusion
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct infusion of shed mediastinal blood (Group I)
Trial: 6539812
Drug: Metoclopramide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (2 mg/kg intravenous every two hours for five doses)
Trial: 6539812
Drug: Haloperidol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (3 mg intravenous every two hours for five doses)
Trial: 29199384
Drug: LED therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED therapy (658 nm) with 40 mW, 7 J/cm2 on every other day
Trial: 26050706
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg oral N-acetylcysteine (NAC) twice daily during AmB treatment
Trial: 22275504
Drug: Autologous CIK
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous CIK cell immunotherapy
Trial: 22275504
Drug: Interleukin-2 treatment
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interleukin-2 treatment combination with IFN-α-2a
Trial: 20637967
Drug: 21-mg/24-hour patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21-mg/24-hour patch
Trial: 20637967
Drug: 25-mg/16-hour patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-mg/16-hour patch
Trial: 20637967
Drug: 21-mg/24-hour patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21-mg/24-hour patch (16-hour application time)
Trial: 16466061
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc sulphate (50 mg of elemental zinc)
Trial: 9413354
Drug: Eflornithine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflornithine (0.5 to 3 g/m2 daily for 6 to 12 months in phase 1; 0.5 g/m2 for 12 months in phase 2)
Trial: 3555956
Drug: Semi-synthetic human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-synthetic human insulin
Trial: 3555956
Drug: Treatment periods
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment periods in chronological order
Trial: 30666366
Drug: SOMS-guided mobility
RxNorm normalized name: Wal-Som
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SOMS-guided mobility treatment with a facilitator
Trial: 24606242
Drug: NoRx (open-label
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NoRx (open-label 'no treatment')
Trial: 21704889
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with standardized house dust mite extract
Trial: 18187431
Drug: Glucomannan (Propol)
DrugBank: Konjac mannan (DB14963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucomannan (Propol) 2 x 1.3 gr daily for two months
Trial: 18187431
Drug: Placebo powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo powder daily for two months
Trial: 15210522
Drug: Embryonic tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Embryonic tissue implants
Trial: 11454015
Drug: Gemfibrozil (GF),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (GF), 600 mg b.i.d. for 12 weeks
Trial: 7823273
Drug: Guided tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided tissue regeneration with metronidazole gel (25%, 250 mg/g)
Trial: 7823273
Drug: Guided tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided tissue regeneration without metronidazole gel (control)
Trial: 2898321
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg metaclazepam per day for 13 days
Trial: 2898321
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg bromazepam per day for 13 days
Trial: 21316208
Drug: DHA+AA (220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA+AA (220 mg/day)
Trial: 18494204
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy in open cholecystectomy
Trial: 17159063
Drug: CRT-defibrillator therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT-defibrillator therapy
Trial: 17159063
Drug: CRT therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT therapy
Trial: 17159063
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of neurohormonal antagonists
Trial: 8459990
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg i.v. 0, 4 and 8 h following chemotherapy)
Trial: 8459990
Drug: Metoclopramide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (3 mg/kg i.v. followed by an infusion of 0.5 mg/kg/h for 8 h)
Trial: 8459990
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg) with dexamethasone (16 mg) before chemotherapy followed by oral dosing with 8 mg ondansetron 3 times daily for 5 days
Trial: 8459990
Drug: Metoclopramide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (60 mg) with dexamethasone (16 mg) before chemotherapy followed by oral dosing with 20 mg metoclopramide 3 times daily for 5 days
Trial: 8459990
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg) given orally twice daily
Trial: 3816928
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone 1 g
Trial: 3816928
Drug: Intraperitoneal ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal ceftriaxone 1 g
Trial: 2468447
Drug: 5% albumin
RxNorm normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% albumin infusion
Trial: 22614886
Drug: Early antiretroviral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antiretroviral therapy (ART) initiated before 3 months of age
Trial: 11836563
Drug: 5'-DFUR treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'-DFUR treatment for 6 months